NewsRoom Articles - BioMedWire (BMW)

FridayOct 31, 2025 10:00 am

How Rural Health Care is Being Impacted by the Federal Funding Landscape

Approximately 20% of people in the U.S. live in a rural area, and they face unique health challenges, such as higher rates of diabetes, obesity and high blood pressure. The recent changes to health care funding brought by the Big Beautiful Bill signed into law in early July are likely to impact rural areas adversely. Kimberly MacPherson, a health policy lecturer at UC Berkeley, highlights how rural health will be impacted. She says the rates of individuals on Medicaid are generally higher in rural areas, so the cuts to funding are bound to have a disproportionate impact upon these people.…

ThursdayOct 30, 2025 10:00 am

$37.5M Grant Announced to Boost Management of Infectious Diseases in the US

On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant of $37.5 million targeting HCIDs (High-Consequence Infectious Diseases). Laboratories that do work related to high-consequence pathology and pathogens were urged to call upon their employers to apply and be included among the 75 health care facilities that will be selected to receive part of this large grant. The purpose of this award is to upgrade or provide the chosen facilities with what they need to become recognized as Level 2 NSPS centers having special pathogen management systems. The hospitals selected will receive a maximum of…

TuesdayOct 28, 2025 10:00 am

What Patients Need to Know About the Remission Rate of Glioblastomas

Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer. It resists existing treatments and recurs in all patients, with a relatively short survival time averaging 14-18 months. Understanding the rate of remission for this disease can therefore enable patients and their caregivers to have a clear picture of what to expect, and therefore be guided in making any decisions they need to make. We discuss some of the factors influencing remission in GBM. It is important to note that GBM tumors almost always regrow, so remission in this case should be viewed as the…

TuesdayOct 28, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C. Soligenix’s ThermoVax(R) technology has broad applicability in Emerging Infectious Disease. Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published a peer-reviewed summary of new…

FridayOct 24, 2025 10:00 am

New LED Therapy Kills Cancer Cells While Sparing Healthy Tissues

Many existing cancer treatments, such as chemotherapy and radiation, don’t distinguish between cancer cells and healthy body cells, and the healthy cells killed alongside cancer cells result in harsh side effects. Researchers are constantly looking for new treatments that are better able to target cancer cells while leaving healthy cells untouched. A new study seems to have uncovered a therapy that could do just that. The study, conducted through a collaboration between a team at University of Texas, Austin, and another team at the University of Porto, Portugal, leveraged a combination of using nano-sized tin particles together with LED light.…

ThursdayOct 23, 2025 10:00 am

New Study Provides Insights on the Cost of Treating Firearm Injuries in America

A study whose findings were recently published has provided insights into the cost of treating injuries resulting from firearms, with a key finding being that Medicaid was billed for a little more than half of the total amount of money spent on these injuries during the period covered by the study. The study, which was conducted by a joint team from the University of Michigan and Northwestern University in Illinois, focused on the initial treatment that individuals received when they visited a hospital after sustaining firearm injuries. For their study, the researchers obtained data on inpatient and emergency department visits…

WednesdayOct 22, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions IZOZF’s innovative approaches highlight the company’s mission to improve diagnosis, detection, and care for people globally Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the…

TuesdayOct 21, 2025 10:00 am

Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD

In the U.S., liver disease claims the lives of at least 52,000 people annually. Globally, statistics suggest that 1.5 billion individuals are affected by liver disease. However, ARLD, or alcohol-related liver disease, hasn’t garnered traction within the scientific community, until now. A study undertaken by a team at Texas A&M University has developed a novel therapy that could transform how ARLD is treated. Doctor Jyothi Menon, the lead researcher of this study, explains that the rising cases of liver diseases increase the risk of potentially life-threatening complications like cancer developing from these liver diseases. She adds that this concern drove…

TuesdayOct 21, 2025 9:00 am

Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for enhanced breast cancer drug delivery 20nm Deciparticle(TM) achieves full bioavailability: Intravenous delivery of Everolimus (Afinitor(R)) maximizes tumor targeting and efficacy compared to 10% absorption with oral formulations Rapid IND platform accelerates pipeline: Strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores…

FridayOct 17, 2025 10:00 am

Virtual Brain Tumors Could Transform How Cancer is Treated

Brain tumors, such as glioblastoma, are very hard to treat and even surgery isn’t sufficient to fully remove the tumor since tiny particles of cancerous cells remain and proliferate within a short time. However, ongoing work at Cedars-Sinai promises to transform brain cancer treatment by creating a digital twin of a patient’s tumor and then predicting how the cancer will grow and how it could respond to different therapies. In this way, treatment teams can better personalize treatments for individual patients. At the heart of this work is Kristin Swanson, PhD, who is engaged in pioneering work that combines mathematics…